September 2025

UROLOGY

FDA APPROVES PRACTICE-CHANGING NOVEL THERAPY FOR BLADDER CANCER

In this episode of Better Edge, Joshua Meeks, MD, PhD, discusses the FDA's recent approval of the gemcitabine intravesical system Inlexzp (formerly TAR-200), a novel therapy for BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC). Having played a key role in its clinical development through Northwestern Medicine's leadership in SunRISe studies, Dr. Meeks explores its potential to transform patient care.
Joshua Meeks, MD, PhD, the Edward M. Schaeffer, MD, PhD Professor of Urology, and Associate Professor of Urology at Northwestern Medicine

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like